References(29)
[1]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359-E386.
[2]
Vogelstein, B.; Papadopoulos, N.; Velculescu, V. E.; Zhou, S.; Diaz, L. A.; Kinzler, K. W. Cancer genome landscapes. Science 2013, 339, 1546-1558.
[3]
McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W. T.; Chang, F. M.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A. et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773, 1263-1284.
[4]
Brink, M.; de Goeij, A. F. P. M.; Weijenberg, M. P.; Roemen, G. M. J. M.; Lentjes, M. H. F. M.; Pachen, M. M. M.; Smits, K. M.; de Bruïne, A. P.; Goldbohm, R. A.; van den Brandt, P. A. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003, 24, 703-710.
[5]
Morris, V. K.; Lucas, F. A.; Overman, M. J.; Eng, C.; Morelli, M. P.; Jiang, Z. Q.; Luthra, R.; Meric-Bernstam, F.; Maru, D.; Scheet, P. et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann. Oncol .2014, 25, 2008-2014.
[6]
Jonker, D. J.; O'Callaghan, C. J.; Karapetis, C. S.; Zalcberg, J. R.; Tu, D. S.; Au, H. J.; Berry, S. R.; Krahn, M.; Price, T.; Simes, R. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med .2007, 357, 2040-2048.
[7]
Dasari, A.; Messersmith, W. A. New strategies in colorectal cancer: Biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin. Cancer Res .2010, 16, 3811-3818.
[8]
Karapetis, C. S.; Khambata-Ford, S.; Jonker, D. J.; O’Callaghan, C. J.; Tu, D. S.; Tebbutt, N. C.; Simes, R. J.; Chalchal, H.; Shapiro, J. D.; Robitaille, S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med .2008, 359, 1757-1765.
[9]
Segelov, E.; Chan, D.; Shapiro, J.; Price, T. J.; Karapetis, C. S.; Tebbutt, N. C.; Pavlakis, N. The role of biological therapy in metastatic colorectal cancer after first-line treatment: A meta-analysis of randomised trials. Br. J. Cancer 2014, 111, 1122-1231.
[10]
Van Cutsem, E.; Cervantes, A.; Nordlinger, B.; Arnold, D.; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol .2014, 25, iii1-9.
[11]
Cho, S. W.; Kim, S.; Kim, J. M.; Kim, J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol .2013, 31, 230-232.
[12]
Fu, Y. F.; Foden, J. A.; Khayter, C.; Maeder, M. L.; Reyon, D.; Joung, J. K.; Sander, J. D. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol .2013, 31, 822-826.
[13]
Kim, H.; Kim, S. T.; Ryu, J.; Kang, B. C.; Kim, J. S.; Kim, S. G. CRISPR/Cpf1-mediated DNA-free plant genome editing. Nat. Commun .2017, 8, 14406.
[14]
Liu, J. W.; Jiang, X. M.; Ashley, C.; Brinker, C. J. Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J. Am. Chem. Soc .2009, 131, 7567-7569.
[15]
Wang, M.; Zuris, J. A.; Meng, F. T.; Rees, H.; Sun, S.; Deng, P.; Han, Y.; Gao, X.; Pouli, D.; Wu, Q. et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc. Natl. Acad. Sci. USA 2016, 113, 2868-2873.
[16]
Kobayashi, H.; Watanabe, R.; Choyke, P. L. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 2014, 4, 81-89.
[17]
Haeussler, M.; Schönig, K.; Eckert, H.; Eschstruth, A.; Mianné, J.; Renaud, J. B.; Schneider-Maunoury, S.; Shkumatava, A.; Teboul, L.; Kent, J. et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol .2016, 17, 148.
[18]
van Hoogevest, P.; Wendel, A. The use of natural and synthetic phospholipids as pharmaceutical excipients. Eur. J. Lipid Sci. Technol .2014, 116, 1088-1107.
[19]
Cho, E. Y.; Ryu, J. Y.; Lee, H. A. R.; Hong, S. H.; Park, H. S.; Hong, K. S.; Park, S. G.; Kim, H. P.; Yoon, T. J. Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. J. Nanobiotechnology 2019, 17, 19.
[20]
Nam, H. Y.; Kwon, S. M.; Chung, H.; Lee, S. Y.; Kwon, S. H.; Jeon, H.; Kim, Y.; Park, J. H.; Kim, J.; Her, S. et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Control Release 2009, 135, 259-267.
[21]
Wang, L. H.; Rothberg, K. G.; Anderson, R. G. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J. Cell Biol .1993, 123, 1107-1117.
[22]
Gao, H. L.; Yang, Z.; Zhang, S.; Cao, S. J.; Shen, S.; Pang, Z. Q.; Jiang, X. G. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci. Rep .2013, 3, 2534.
[23]
Kim, W. H.; Yeo, M.; Kim, M. S.; Chun, S. B.; Shin, E. C.; Park, J. H.; Park, I. S. Role of caspase-3 in apoptosis of colon cancer cells induced by nonsteroidal anti-inflammatory drugs. Int. J. Colorectal Dis .2000, 15, 105-111.
[24]
Veluchamy, J. P.; Lopez-Lastra, S.; Spanholtz, J.; Bohme, F.; Kok, N.; Heideman, D. A. M.; Verheul, H. M. W.; Di Santo, J. P.; de Gruijl, T. D.; van der Vliet, H. J. In vivo efficacy of umbilical cord blood stem cell-derived NK cells in the treatment of metastatic colorectal cancer. Front. Immunol .2017, 8, 87.
[25]
Roper, J.; Tammela, T.; Cetinbas, N. M.; Akkad, A.; Roghanian, A.; Rickelt, S.; Almeqdadi, M.; Wu, K.; Oberli, M. A.; Sánchez-Rivera, F. J. et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat. Biotechnol .2017, 35, 569-576.
[26]
Yi, L.; Li, J. M. CRISPR-Cas9 therapeutics in cancer: Promising strategies and present challenges. Biochim. Biophys. Acta 2016, 1866, 197-207.
[27]
Liu, C.; Zhang, L.; Liu, H.; Cheng, K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J. Control Release 2017, 266, 17-26.
[28]
Staahl, B. T.; Benekareddy, M.; Coulon-Bainier, C.; Banfal, A. A.; Floor, S. N.; Sabo, J. K.; Urnes, C.; Munares, G. A.; Ghosh, A.; Doudna, J. A. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat. Biotechnol .2017, 35, 431-434.
[29]
Zuris, J. A.; Thompson, D. B.; Shu, Y. L.; Guilinger, J. P.; Bessen, J. L.; Hu, J. H.; Maeder, M. L.; Joung, J. K.; Chen, Z. Y.; Liu, D. R. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol .2015, 33, 73-80.